Application of the linear-quadratic model to radioimmunotherapy: Confirmation of the advantage of longer-lived radionuclides

Journal Article · Sun May 01 04:00:00 EDT 1994 · Journal of Nuclear Medicine

OSTI ID:197989

Howell, R W; Goddu, S M; Rao, D V ^[1]

---

1. UMDNJNJ Medical School, Newark, NJ (United States)

Radioimmunotherapy (RIT), as it is currently practiced, delivers low doses to tumors primarily because of dose-limiting bone marrow toxicity. The biological effectiveness of RIT depends on the total dose, dose rate, and the fractionation schedule of the radiolabeled antibodies administered. An approach, based on the linear-quadratic model (LQ) which is routinely used in conventional radiotherapy, is advanced for applications in RIT. This approach incorporates repair rates, biological half-lives of the antibodies, physical half-lives of the radionuclides employed, dose rates, and total doses needed for a given biological effect. The LQ approach yields predictions similar to those based on our earlier TDF approach and reaffirms that relatively long-lived radionuclides coupled to monoclonal antibodies are indeed more likely to deliver therapeutically effective doses to tumors than the shorter-lived nuclides presently in use. Several radionuclides (Y-90, I-131, P-32, In-114m) are evaluated in this context.

• OSTI ID: 197989
• Report Number(s): CONF-940605--; CNN: Grant CA32877; Grant CA54891
• Journal Information: Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: Suppl.5 Vol. 35; ISSN 0161-5505; ISSN JNMEAQ
• Country of Publication: United States
• Language: English

Related Subjects

55 BIOLOGY AND MEDICINE
BASIC STUDIES
99 GENERAL AND MISCELLANEOUS
BONE MARROW
DOSE RATES
FRACTIONATION
INDIUM 114
IODINE 131
MONOCLONAL ANTIBODIES
PERFORMANCE
PHOSPHORUS 32
RADIOIMMUNOTHERAPY
TOXICITY
YTTRIUM 90